SYNAIRGEN PLC LS-01
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. Synairgen plc was incorporated in 2004 and is headquart… Read more
Market Cap & Net Worth: SYNAIRGEN PLC LS-01 (OMY)
SYNAIRGEN PLC LS-01 (F:OMY) has a market capitalization of $7.92 Million (€7.72 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #35593 globally and #4231 in its home market, demonstrating a 27.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SYNAIRGEN PLC LS-01's stock price €0.01 by its total outstanding shares 1102659968 (1.10 Billion).
SYNAIRGEN PLC LS-01 Market Cap History: 2020 to 2025
SYNAIRGEN PLC LS-01's market capitalization history from 2020 to 2025. Data shows change from $1.75 Billion to $7.92 Million (-57.89% CAGR).
SYNAIRGEN PLC LS-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SYNAIRGEN PLC LS-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OMY by Market Capitalization
Companies near SYNAIRGEN PLC LS-01 in the global market cap rankings as of March 19, 2026.
Key companies related to SYNAIRGEN PLC LS-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SYNAIRGEN PLC LS-01 Historical Marketcap From 2020 to 2025
Between 2020 and today, SYNAIRGEN PLC LS-01's market cap moved from $1.75 Billion to $ 7.92 Million, with a yearly change of -57.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €7.92 Million | -75.86% |
| 2024 | €32.82 Million | -42.57% |
| 2023 | €57.16 Million | -57.99% |
| 2022 | €136.05 Million | -94.92% |
| 2021 | €2.68 Billion | +52.52% |
| 2020 | €1.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SYNAIRGEN PLC LS-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.92 Million USD |
| MoneyControl | $7.92 Million USD |
| MarketWatch | $7.92 Million USD |
| marketcap.company | $7.92 Million USD |
| Reuters | $7.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.